| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1052193116 |
| P356 | DOI | 10.1208/S12249-010-9393-0 |
| P932 | PMC publication ID | 2850475 |
| P698 | PubMed publication ID | 20238190 |
| P5875 | ResearchGate publication ID | 42256221 |
| P2093 | author name string | Alekha K Dash | |
| William J Trickler | |||
| Ankita A Nagvekar | |||
| Jatin Khurana | |||
| P2860 | cites work | Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells | Q24651034 |
| A phase I clinical, plasma, and cellular pharmacology study of gemcitabine | Q28334915 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| Cancer statistics, 2006 | Q29615133 | ||
| Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs | Q33222364 | ||
| Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems | Q33223515 | ||
| Preparation of poly epsilon-caprolactone nanoparticles containing magnetite for magnetic drug carrier. | Q33252054 | ||
| Mucoadhesive nanoparticulate systems for peptide drug delivery | Q34184353 | ||
| A novel nanoparticle formulation for sustained paclitaxel delivery | Q34293494 | ||
| Nucleoside transporters in chronic lymphocytic leukaemia | Q35635321 | ||
| Pancreatic cancer: diagnosis and management. | Q36396324 | ||
| Nanoparticles for cellular drug delivery: mechanisms and factors influencing delivery | Q36627043 | ||
| Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines | Q36994110 | ||
| Novel approaches to deliver gemcitabine to cancers | Q37160947 | ||
| The in vitro sub-cellular localization and in vivo efficacy of novel chitosan/GMO nanostructures containing paclitaxel | Q39849321 | ||
| Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent | Q40002504 | ||
| Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. | Q40095319 | ||
| Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules | Q40102884 | ||
| Magnetic poly epsilon-caprolactone nanoparticles containing Fe3O4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model. | Q40110831 | ||
| Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: results of an in vitro and in vivo study | Q40214199 | ||
| A mucoadhesive in situ gel delivery system for paclitaxel | Q40263358 | ||
| Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors | Q40531924 | ||
| Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis | Q40632272 | ||
| Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery | Q40713744 | ||
| In vitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron-capture therapy of cancer | Q40759040 | ||
| Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. | Q40776900 | ||
| [3H]gemcitabine uptake by nucleoside transporters in a human head and neck squamous carcinoma cell line | Q40971672 | ||
| Preclinical characteristics of gemcitabine. | Q41040899 | ||
| Differential mucin gene expression in human pancreatic and colon cancer cells | Q41679123 | ||
| Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). | Q41728002 | ||
| Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines | Q42142458 | ||
| RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. | Q42799200 | ||
| Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine | Q43289065 | ||
| Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. | Q43687728 | ||
| Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage | Q43829332 | ||
| Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels | Q43971548 | ||
| A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform | Q44401579 | ||
| A novel in situ gel for sustained drug delivery and targeting | Q44869101 | ||
| Preparation of gemcitabine polybutylcyanoacrylate nanoparticles | Q46892442 | ||
| The mechanism of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine) in a pancreatic cancer cell line | Q46948429 | ||
| Magnetic PECA nanoparticles as drug carriers for targeted delivery: synthesis and release characteristics. | Q51186635 | ||
| Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. | Q54122138 | ||
| Nanoparticles based on N-trimethylchitosan: Evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models | Q57360670 | ||
| Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine | Q68408993 | ||
| Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes | Q71499864 | ||
| Mucoadhesion of polymer-coated liposomes to rat intestine in vitro | Q72791120 | ||
| Tumor pH: implications for treatment and novel drug design | Q74676183 | ||
| Interaction of 2',2'-difluorodeoxycytidine (gemcitabine) and formycin B with the Na+-dependent and -independent nucleoside transporters of Ehrlich ascites tumor cells | Q77223754 | ||
| Thiomers: preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system | Q83087906 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| nanostructure | Q1093894 | ||
| P304 | page(s) | 392-401 | |
| P577 | publication date | 2010-03-18 | |
| P1433 | published in | AAPS PharmSciTech | Q15750612 |
| P1476 | title | Chitosan and glyceryl monooleate nanostructures containing gemcitabine: potential delivery system for pancreatic cancer treatment | |
| P478 | volume | 11 |
| Q38091630 | Advances in chitosan-based drug delivery vehicles |
| Q46968656 | Antitumor efficacy, tumor distribution and blood pharmacokinetics of chitosan/glyceryl-monooleate nanostructures containing paclitaxel |
| Q39346357 | Chitosan-Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study |
| Q46007249 | Effect of high-pressure homogenization and stabilizers on the physicochemical properties of curcumin-loaded glycerol monooleate/chitosan nanostructures. |
| Q50044141 | Fabrication of novel GMO/Eudragit E100 nanostructures for enhancing oral bioavailability of carvedilol |
| Q47199315 | Gemcitabine hydrochloride-loaded liposomes and nanoparticles: comparison of encapsulation efficiency, drug release, particle size, and cytotoxicity |
| Q31098128 | Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells |
| Q35024399 | Multifunctional nanoparticles for prostate cancer therapy |
| Q60959037 | Silver Nanoparticles Potentiates Cytotoxicity and Apoptotic Potential of Camptothecin in Human Cervical Cancer Cells |
| Q33659863 | Silver nanoparticle induced blood-brain barrier inflammation and increased permeability in primary rat brain microvessel endothelial cells |
| Q39588127 | Surface-modified gemcitabine with mucoadhesive polymer for oral delivery. |
| Q46218236 | Surface-modified solid lipid nanoparticulate formulation for ifosfamide: development and characterization |
Search more.